Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 18/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 18/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 18/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6642002 | 0.99 | ADRA1D (0.54) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL6713785 | 0.87 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL6718413 | 0.87 | ADRA1D (0.68) | ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL6767632 | 0.86 | ADRA1D (0.67) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7065101 | 0.81 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BOPRM1 | |
| Hydrochloric Acid SCHEMBL6787204 | 0.79 | ADRA1A (0.58) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6786591 | 0.77 | ADRA1A (0.60) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL6782753 | 0.77 | ADRA1A (0.51) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6645059 | 0.75 | ADRA1A (0.66) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6784680 | 0.74 | ADRA1A (0.56) | ADRA1DADRA1AADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.